Science Immunology

Supplementary Materials

The PDF file includes:

  • Fig. S1. Relative numbers of tumor-infiltrating T cells to tumor cells in MSS and MSI CRC.
  • Fig. S2. Expression of immune checkpoint inhibitory receptors in CD8+ T cells from the peripheral blood, adjacent normal mucosa, and tumors of patients with CRC.
  • Fig. S3. Expression of immune checkpoint inhibitory receptors in CD8+ T cells from the peripheral blood and adjacent normal mucosa of patients with MSS and MSI CRC.
  • Fig. S4. Expression of CTAG1B in normal adjacent mucosa and tumor tissues.
  • Fig. S5. Production of IFN-γ and TNF in CD8+ TILs upon anti-CD3 and anti-CD28 stimulation.
  • Fig. S6. Expression of upstream regulators of wound healing signature genes in CRC.
  • Fig. S7. Correlation of VEGF-A levels between plasma and tissue homogenates.
  • Fig. S8. Representative histograms for the expression of immune checkpoint receptors on CD8+ T cells stimulated with anti-CD3 antibodies and VEGF-A.
  • Fig. S9. Expression of immune checkpoint receptors on CD8+ T cells treated with VEGF-A in the absence of anti-CD3 stimulation.
  • Fig. S10. Correlation between VEGF-A expression and T cell infiltration in MSS CRC.
  • Fig. S11. Effects of NFATc1 inhibition on CD8+ T cells.
  • Fig. S12. H3K27ac ChIP-seq analysis for control siRNA– or TOX siRNA–transfected CD8+ T cells after anti-CD3 and VEGF-A treatment.
  • Fig. S13. GSEA analysis of tumor-infiltrating CD8+ T cell transcriptomes.
  • Fig. S14. Expression of TOX in CD8+ T cells from the peripheral blood and adjacent normal mucosa of MSS and MSI CRC patients.
  • Fig. S15. Characteristics of NY-ESO-1157-165–specific CD8+ T cell lines.
  • Fig. S16. Effects of the blockade of PD-1 and VEGF-A on the function of tumor-infiltrating CD8+ T cells.
  • Fig. S17. Effects of the blockade of PD-1, VEGFR2, and VEGF-A on the phenotype of tumor-infiltrating CD8+ T cells.
  • Fig. S18. Expression of wound healing signature genes and VEGF-A in MC38-OVA tumor tissues.
  • Fig. S19. Effects of T cell depletion in vivo.
  • Fig. S20. Expression of VEGFR2 in tumor-infiltrating CD8+ T cells from wild-type and T cell–specific VEGFR2 conditional knockout mice.
  • Fig. S21. Effects of in vivo blockade of PD-1 and VEGFR2 on the phenotype of OVA257-265-specific, tumor-infiltrating CD8+ T cells.

Download PDF

Other Supplementary Material for this manuscript includes the following:

  • Table S1. Raw data (Excel).
  • Table S2. List of transcription factors up-regulated by VEGF-A treatment in CD8+ T cells during antigen recognition Log2(fold change) > 2 and adjusted P < 0.05; Excel.
  • Table S3. List of patients (Excel).
  • Table S4. Key resources (Excel).

Files in this Data Supplement: